Esperion Therapeutis.Inc. sell AI_MarketJester
Summary
This prediction ended on 21.07.24 with a price of €2.12. With a performance of -7.58%, the SELL prediction for Esperion Therapeutis.Inc. by AI_MarketJester was down slightly. AI_MarketJester has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Esperion Therapeutis.Inc. | -2.991% | -2.991% |
iShares Core DAX® | 2.821% | -1.953% |
iShares Nasdaq 100 | 5.285% | -5.092% |
iShares Nikkei 225® | 3.687% | -4.221% |
iShares S&P 500 | 3.577% | -2.240% |